Phylogica Limited

01/03/2018 | Press release | Distributed by Public on 01/03/2018 19:16

Appointment of Non-Executive Director and Appendix 3X

ASX ANNOUNCEMENT

Appointment of Non-Executive Director

PERTH, Australia, 3 January 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug development and delivery platform technology, is pleased to announce the appointment of Michael Williams as Non-Executive Director.

Mr Williams is a senior pharmaceutical executive with significant global experience, most recently as Chief Operating Officer at Intarcia Therapeutics. Prior to Intarcia Therapeutics Mr Williams was Head of Global Marketing at Takeda Pharmaceuticals.

Before joining Takeda, he was Vice President, Global Commercial Development for

Pfizer's Primary Care Global Business Unit. He also played a significant leadership role in Pfizer's acquisition of King Pharmaceuticals and on alliances with Bristol Myers Squibb, Boehringer Ingelheim, Janssen and Eisai. During his time at Bristol Myers Squibb, he assumed roles of increasing responsibility notably Regional Business lead for HIV where he was responsible for the commercial performance of the HIV franchise as well as Vice President for European Marketing and Operations.

In joining Phylogica, Mr Williams stated "I am delighted to join the Phylogica Board at such an exciting time for the Company. Phylogica's drug delivery platform has the potential to transform drug discovery and development across the Biopharmaceutical industry. I am excited to be able to support the Phylogica team in developing new partnerships across the healthcare industry."

Commenting on the appointment, Phylogica CEO Stephanie Unwin said, "Michael brings his many years of Pharma executive expertise to the Board at time when we are transforming the Company to form strategic partnerships and commercial alliances in the Pharma industry. The skill sets and deep capability Michael has across alliances; acquisitions; business performance and commercial deal making is a huge asset for us.

He is well known in the pharmaceutical world for innovative thinking and his deep knowledge of global healthcare markets adds seasoned strategic commercial capability to the Board as we commercialise Phylogica's unique platform technology."

ENDS

For further information, please contact:

About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company's lead asset program has identified a Phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has had collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and currently with Genentech.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. Phylogica undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by Phylogica. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

www.phylogica.com

Phylogica Ltd ABN 48 098 391 96

Appendix 3X

Initial Director's Interest Notice

24.Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity PHYLOGICA LIMITED

ACN

098 391 961

We Phylogica Limited give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director

MICHAEL WiLLIAMS

Date of Appointment

3 January 2018

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Number & class of securities

NIL

+ See chapter 19 for defined terms.

30/9/2001

Appendix 3X Page 1

Appendix 3X

Initial Director's Interest Notice

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest

Note: Provide details of the circumstances giving rise to the relevant interest.

Number & class of Securities

NIL

Part 3 - Director's interests in contracts

Detail of contract

NIL

Nature of interest

Name of registered holder (if issued securities)

No. and class of securities to which interest relates

+ See chapter 19 for defined terms.

Appendix 3X Page 2

30/9/2001